Remibrutinib shows strong sleep improvement data in CSU

Novartis (NOVN: VX) has reported new data showing that its investigational BTK inhibitor, remibrutinib, significantly improves sleep quality for patients with chronic spontaneous urticaria (CSU). The findings, from the Phase III REMIX-1 and REMIX-2 trials, were presented at the American Academy of Dermatology annual meeting in Orlando.

The results build on previously reported data supporting the drug’s ability to reduce symptoms of the condition, which causes unpredictable and persistent hives. At the 24-week mark, 58.9% of patients in the REMIX-1 study and 58.2% in REMIX-2 reported no disruption to sleep, compared to 44.2% and 41.2% of those given a placebo. 

These improvements in sleep add to the drug’s strong efficacy profile, with the Swiss pharma giant having already reported that remibrutinib met its primary endpoints in the REMIX studies by significantly reducing CSU symptoms.